Related Experiment Video
Updated: Jun 21, 2026
Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model
Published on: March 6, 2012
The Role of Radiotherapy in Indolent Ocular Adnexal and Orbital Lymphomas
Gozde Yazici1, Serkan Akin2, Alper Kahvecioglu1
1Faculty of Medicine, Department of Radiation Oncology, Hacettepe University, Ankara, Turkey.
Background:
This study evaluates the oncological outcomes and toxicities of indolent ocular adnexal and orbital lymphomas (OOLs) treated with radiotherapy (RT) ± systemic therapy.
Methods:
A retrospective analysis of 44 patients with indolent OOLs treated with RT was conducted.
Results:
Most patients (87%) had early-stage disease. Treatment involved RT alone (34%) or RT + systemic therapy (66%). The median RT dose was 30 Gy, with a median follow-up of 45 months. Local and systemic recurrence rates were 4% and 9%, respectively. Five-year overall and disease-free survival (DFS) rates were 96.2% and 83.6%. Early-stage patients showed similar DFS rates regardless of whether they received RT alone or RT plus systemic therapy. No grade 3 RT-related toxicity occurred, but systemic therapy led to grade 3 toxicity in 17% of patients.
Conclusions:
RT is essential for treating indolent OOLs, and combination with systemic therapies does not enhance outcomes for early-stage patients.
More Related Videos
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy